Dr Farasat Kazmi

Dr Farasat Kazmi is a Consultant Clinical Oncologist specialising in lung cancer, with particular expertise in advanced radiotherapy techniques including Stereotactic Ablative Radiotherapy (SABR). He treats lung cancer across all stages, from early-stage disease to locally advanced and metastatic cancer, using modern radiotherapy alongside chemotherapy, immunotherapy, and precision-targeted therapies guided by molecular profiling.

Dr Kazmi has a strong academic and research background and holds an MSc in Nanomedicine from the University of Oxford. He previously worked in the Early Phase Clinical Trials Unit at the Churchill Hospital, Oxford, where he was involved in first-in-human and novel targeted therapy studies. He is the Principal Investigator on three international lung cancer clinical trials and has played a leading role in Cochrane systematic reviews on genomic-guided cancer therapies, ensuring his clinical practice is firmly grounded in the highest-quality evidence.

He is actively involved in precision oncology, leading institutional initiatives focused on integrating molecular testing and personalised treatment strategies into routine cancer care. His work has been recognised through national and international awards, including competitive oncology research and education grants.

In addition to lung cancer, Dr Kazmi treats gynaecological cancers, including ovarian cancer, and non-melanoma skin cancers.

He is known for his clear communication, calm manner, and patient-centred approach, taking time to explain diagnoses and treatment options and supporting shared decision-making throughout the cancer journey.